[go: up one dir, main page]

RU2002130200A - Композиции для доставки лекарственного средства - Google Patents

Композиции для доставки лекарственного средства

Info

Publication number
RU2002130200A
RU2002130200A RU2002130200/15A RU2002130200A RU2002130200A RU 2002130200 A RU2002130200 A RU 2002130200A RU 2002130200/15 A RU2002130200/15 A RU 2002130200/15A RU 2002130200 A RU2002130200 A RU 2002130200A RU 2002130200 A RU2002130200 A RU 2002130200A
Authority
RU
Russia
Prior art keywords
polynucleotide
composition according
specified
composition
histone
Prior art date
Application number
RU2002130200/15A
Other languages
English (en)
Inventor
Андреа КРИСАНТИ (GB)
Андреа КРИСАНТИ
Селма ЭССЕГИР (GB)
Селма ЭССЕГИР
Original Assignee
Импликс Лтд. (Gb)
Импликс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0009080A external-priority patent/GB0009080D0/en
Priority claimed from GB0102667A external-priority patent/GB0102667D0/en
Application filed by Импликс Лтд. (Gb), Импликс Лтд. filed Critical Импликс Лтд. (Gb)
Publication of RU2002130200A publication Critical patent/RU2002130200A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Claims (8)

1. Композиция, содержащая конъюгат полинуклеотида и гистонового белка или фрагмента указанного белка, который сохраняет способность связываться с полинуклеотидом и подвергаться трансфекции, причем, указанная композиция не содержит сыворотки, ионов кальция, хлорохина и катионных липидов и предназначена для терапевтического применения.
2. Композиция по п.1, где указанным гистоновым белком является гистон H1.
3. Композиция, содержащая гистоновый белок, включающий в себя аминокислотную последовательность, определяемую здесь как SEQ ID NO:2, и полинуклеотид.
4. Композиция по п.3, где указанным полинуклеотидом является ДНК.
5. Композиция по п.3, где указанным полинуклеотидом является РНК.
6. Композиция по любому из пп.3-5 для терапевтического применения.
7. Гистоновый белок для трансфекции полинуклеотида, состоящий из аминокислотной последовательности SEQ ID NO:2.
8. Композиция по любому из пп.1-6 в качестве активного ингредиента для изготовления лекарственного средства для внутримышечного или внутрикожного введения для лечения заболевания.
RU2002130200/15A 2000-04-12 2001-04-12 Композиции для доставки лекарственного средства RU2002130200A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0009080A GB0009080D0 (en) 2000-04-12 2000-04-12 Drug delivery
GB0009080.3 2000-04-12
GB0102667.3 2001-02-02
GB0102667A GB0102667D0 (en) 2001-02-02 2001-02-02 Drug delivery

Publications (1)

Publication Number Publication Date
RU2002130200A true RU2002130200A (ru) 2004-03-27

Family

ID=26244096

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2002130200/15A RU2002130200A (ru) 2000-04-12 2001-04-12 Композиции для доставки лекарственного средства
RU2002130203/15A RU2002130203A (ru) 2000-04-12 2001-04-12 Пептидные конъюгаты для доставки лекарственного средства

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2002130203/15A RU2002130203A (ru) 2000-04-12 2001-04-12 Пептидные конъюгаты для доставки лекарственного средства

Country Status (9)

Country Link
US (1) US20040110928A1 (ru)
EP (2) EP1272221A2 (ru)
JP (2) JP2003530360A (ru)
AU (2) AU4674101A (ru)
CA (2) CA2406233A1 (ru)
IL (2) IL151910A0 (ru)
NZ (2) NZ521563A (ru)
RU (2) RU2002130200A (ru)
WO (2) WO2001076637A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2640247C2 (ru) * 2007-04-05 2017-12-27 Зюмбиотек Гезелльшафт Цур Форшунг Унд Энтвиклунг Ауф Дем Гебит Дер Биотехнологи Мбх БИС-Met-ГИСТОНЫ

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1272221A2 (en) * 2000-04-12 2003-01-08 Implyx Ltd. Peptide conjugates for drug delivery
GB0116047D0 (en) * 2001-06-29 2001-08-22 Implyx Ltd Peptide motif for therapy
US9045739B2 (en) * 2004-01-16 2015-06-02 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Immunokinases
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
WO2005117991A2 (en) * 2004-05-04 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
WO2006034277A1 (en) * 2004-09-17 2006-03-30 Comentis, Inc. Bicyclic compounds which inhibit beta-secretase activity and methods of use thereof
JP2008513497A (ja) * 2004-09-17 2008-05-01 コメンティス，インコーポレーテッド メマプシン２βセクレターゼ活性を阻害するアミノ含有化合物およびその使用方法
NZ562314A (en) * 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
GB0507598D0 (en) * 2005-04-14 2005-05-18 Trojantec Technologies Ltd Composition
EP1912678A2 (de) * 2005-08-05 2008-04-23 SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie mbH Verwendung eines biologischen wirkstoffes bei abnormalen zellulären und viralen membranphysiologien
US7858661B2 (en) 2005-08-16 2010-12-28 Sanyo Chemical Industries, Ltd. Protein refolding agent and refolding method
JP4625433B2 (ja) * 2005-08-16 2011-02-02 三洋化成工業株式会社 タンパク質のリフォールディング剤およびリフォールディング方法
CA2628113A1 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
EP1800695A1 (en) * 2005-12-21 2007-06-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immuno-RNA-constructs
ES2570334T3 (es) 2006-06-02 2016-05-17 Harvard College Remodelado superficial de proteínas
CN101828113B (zh) * 2007-07-25 2014-04-16 德国弗劳恩霍夫协会债权安格万特学术研究所 自结合重组抗体融合蛋白
CA2697166A1 (en) * 2007-07-26 2009-01-29 Comentis, Inc. Isophthalamide derivatives inhibiting betasecretase activity
CN101868457B (zh) * 2007-09-24 2013-02-13 科门蒂斯公司 作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物
EP2297182A4 (en) * 2008-04-28 2012-08-15 Harvard College HIGHLY CHARGED PROTEINS USED FOR CELL PENETRATION
JP2012525146A (ja) 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE256148C (ru) *
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
DE4005152A1 (de) * 1990-02-17 1991-08-22 Guenter Prof Dr Kahl Verbesserung der transformation von pflanzenzellen
CA2090355C (en) * 1993-02-25 1997-04-08 Jian Chen Method of gene transfer using galactosylated histones
GB9422495D0 (en) * 1994-11-08 1995-01-04 Medical Res Council DNA transfer method
FR2730637B1 (fr) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
WO1996041606A2 (en) * 1995-06-08 1996-12-27 Therexsys Limited Improved pharmaceutical compositions for gene therapy
US5744335A (en) * 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
EP0967288A1 (en) * 1998-06-16 1999-12-29 Hoechst Marion Roussel Deutschland GmbH Transfection system for the transfer of nucleic acids into cells
EP0908521A1 (en) * 1997-10-10 1999-04-14 Hoechst Marion Roussel Deutschland GmbH Transfection system for the transfer of nucleic acids into cells
EP1272221A2 (en) * 2000-04-12 2003-01-08 Implyx Ltd. Peptide conjugates for drug delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2640247C2 (ru) * 2007-04-05 2017-12-27 Зюмбиотек Гезелльшафт Цур Форшунг Унд Энтвиклунг Ауф Дем Гебит Дер Биотехнологи Мбх БИС-Met-ГИСТОНЫ

Also Published As

Publication number Publication date
IL151910A0 (en) 2003-04-10
NZ521563A (en) 2004-05-28
EP1272221A2 (en) 2003-01-08
CA2406233A1 (en) 2001-10-18
CA2406352A1 (en) 2001-10-18
JP2004528266A (ja) 2004-09-16
NZ521564A (en) 2004-06-25
AU4674101A (en) 2001-10-23
EP1272222A2 (en) 2003-01-08
RU2002130203A (ru) 2004-03-27
JP2003530360A (ja) 2003-10-14
WO2001076637A3 (en) 2002-05-23
US20040110928A1 (en) 2004-06-10
WO2001076638A3 (en) 2002-05-16
WO2001076638A2 (en) 2001-10-18
IL151909A0 (en) 2003-04-10
AU4673901A (en) 2001-10-23
WO2001076637A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
RU2002130200A (ru) Композиции для доставки лекарственного средства
RU2468080C2 (ru) Новый класс терапевтических белковых молекул
JP6406793B2 (ja) トール様受容体に基づく免疫反応を調整する免疫調節ヌクレオチド（ｉｒｏ）化合物
BR0212897A (pt) Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
JP2012505221A (ja) 高コレステロール血症および高脂血症ならびにそれらに関連する疾患の予防および処置におけるトル様受容体の阻害剤の使用
RU2000124084A (ru) Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты)
EP1975235A3 (en) Porcine circovirus vaccine in recombinant poxvirus
JP2006512300A5 (ru)
JP2003500040A5 (ru)
US10041076B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
PT1511845E (pt) Oligonucleótidos imuno-estimuladores e suas utilizações
JP2006506942A5 (ru)
RU98120519A (ru) Аутоантиген и структурно-родственные ему белки для применения при иммунотерапии аутоиммунных заболеваний
JP2005532067A (ja) 刺激性免疫応答用の核酸組成物
CA2327353A1 (en) Structural proteins of fish pancreatic disease virus and uses thereof
WO2001098522A3 (en) Positively-charged peptide nucleic acid analogs with improved properties
WO2004085461A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
WO2001057069A3 (en) Targeting peptides
ZA9610840B (en) Novel binding agents and the use thereof
BR9809457A (pt) Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia.
JP2005508875A5 (ru)
US20130225479A1 (en) Methods and Compositions for Treating Inflammation
US7879812B2 (en) Immunomodulatory oligonucleotides and methods of use therefor
WO2007024029A1 (en) Antiviral agent and viral replication inhibitor
CA2205564A1 (en) Pharmaceutical compositions comprising nitric oxide-releasing biopolymers